Fieldpoint Private Securities LLC bought a new position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,700 shares of the company’s stock, valued at approximately $171,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Security National Bank of Sioux City Iowa IA increased its holdings in Teva Pharmaceutical Industries by 0.4% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after buying an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the last quarter. Sheaff Brock Investment Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 3.6% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock valued at $279,000 after buying an additional 294 shares during the last quarter. Bank of Nova Scotia increased its holdings in Teva Pharmaceutical Industries by 8.3% in the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after buying an additional 528 shares during the last quarter. Finally, First National Trust Co. increased its holdings in Teva Pharmaceutical Industries by 6.7% in the second quarter. First National Trust Co. now owns 8,878 shares of the company’s stock valued at $295,000 after buying an additional 555 shares during the last quarter. 52.05% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Ltd (NYSE TEVA) traded up $1.02 during mid-day trading on Friday, reaching $18.32. The company’s stock had a trading volume of 46,315,800 shares, compared to its average volume of 16,294,546. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries Ltd has a 12 month low of $10.85 and a 12 month high of $38.31. The firm has a market capitalization of $15,951.20, a P/E ratio of 3.63 and a beta of 0.55.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a $0.085 dividend. The ex-dividend date was Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 1.86%. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.

Several analysts recently weighed in on the company. Credit Suisse Group raised Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and set a $20.00 price objective for the company in a report on Friday. Morgan Stanley raised Teva Pharmaceutical Industries from an “underweight” rating to a “hold” rating and set a $18.00 price objective for the company in a report on Friday. BTIG Research boosted their price objective on Teva Pharmaceutical Industries to $20.00 in a report on Friday. Goldman Sachs Group raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Friday. Finally, Wells Fargo & Company reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Five equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $20.34.

ILLEGAL ACTIVITY NOTICE: “Fieldpoint Private Securities LLC Buys New Stake in Teva Pharmaceutical Industries Ltd (TEVA)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/15/fieldpoint-private-securities-llc-buys-new-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.